Scholar Rock Holding Corporation

Ladies and gentlemen, thank you for standing by and welcome to the Scholar Rock Management Intro and Second Quarter 2020 Financial Results and Business Progress Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you would need to press star 1 on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star 0. I would now like to hand the conference over to your speaker today, to Catherine Hu, Vice President, Investor Relations and Corporate Communications. Thank you. Please go ahead.

Good morning, and thank you for joining us on today's call to provide an update on second quarter 2020 financial results, as well as an introduction to our newly appointed President and CEO, Tony Kingsley, and CFO and Head of Business Operations, Ted Miles. Young Chung, our Chief Medical Officer, will also be joining Tony and Ted on today's call. The webcast slides for this call can be accessed on the Events and Presentations section of the Investor Relations page on the Scholar Rock website. Before I turn it over to Tony, I wanted to note that during today's call, we will be making various statements about Scholar Rock's future expectations, plans, and prospects that constitute forward-looking statements. for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Scholar Rock's actual results may differ materially from those indicated by any four lifting statements as a result of various important factors more fully discussed in the section entitled Risk Factors in our quarterly report on 410Q, as well as other important factors in Scholar Rock's future filings with the Securities and Exchange Commission. Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any future date. We disclaim any obligation to update any forward-looking statements unless required by law. Thank you, and I will now turn the call over to Tony.

Thank you, Catherine, and thank you, everyone, for joining us this morning. ScholarRock is at an inflection point. The company's science is beginning to prove its potential clinical utility. Our programs are moving quickly toward multiple data readouts, and the company has new leadership to take it to the next phase. Let me tell you a little about myself and why I have joined Solid Rock at this time. As described on slide three, I was most recently president and CEO of Tariff Bio, a development stage oncology company. that was acquired by Janssen Pharmaceuticals at the end of 2019. Before Charis, I served as president and COO of the medicines company, and prior to that, led global commercial operations at Biogen. I bring extensive experience in later stage drug development and commercialization, both of which are rapidly becoming critical to ScholarDoc's success. And I have provided both strategic and operational leadership to life sciences companies in times of great transition and growth. That is the profile that the Solid Rock Board was seeking to replace our founding CEO, Nagesh. This was a very planned and purposeful transition and it signals confidence in the future. The fact that I was able to bring on Ted Miles as our CFO and head of business operations almost immediately should also signal to you that this transition is about building for success. Ted has served on our board for nearly two years and knows the company well. You will hear from Ted shortly. Now let me describe what drew me to Swell Rock. Powerful science, great programs, and talented people. I've been impressed with the level of execution and collaboration and commitment to take on tough targets as we work toward the goal of changing medical practice and helping patients suffering from cancer and neuromuscular disease. My conviction on the scientific platform and programs has only increased as I fully immersed into the culture of the company. Going to slide four in our presentation, my top three takeaways are, first, The scientific platform has produced multiple programs with significant therapeutic potential. Our two most advanced programs, SRK015 and SRK181, are advancing quickly at both address markets that are well-developed and growing very rapidly. There are multiple programs at multiple milestones, and that offers near and long-term value inflection points as well as significant strategic optionality. I can clearly see South Rock's growth potential. The science is highly differentiated. The clinical programs are well designed. And as you will see on slide five, we are moving quickly toward multiple milestones over the next 12 months that will elucidate each program's potential to help patients with serious diseases. I believe this slide captures the breadth and depth of our pipeline and demonstrates the power and productivity of our scientific platform and our talented scientists. It also illustrates the key factors that drove my decision to join Solid Rocks. To start with SRK015 in the spinal muscular atrophy, or SMA, we will be reporting interim results from the ongoing Topaz Phase II trial in the fourth quarter, followed by 12-month data in the first half of 2021. Our goal here is to establish SRK015 as the first muscle-directed therapy for patients affected by SMA. Next, we're making rapid progress in building momentum on the DRAGON Phase 1 trial for SRK181, a potential therapeutic backbone to cancer immunotherapy. We are advancing to Part A2 of the study this quarter. evaluate SRK181 in combination with checkpoint inhibitors and will provide an update on dose escalation in the next quarter. We believe we have the key to unlock the power of checkpoint inhibitors. We are the first and only company to specifically target the TGF-beta-1 isoform, which we believe has the potential to improve efficacy in while minimizing the risks of adverse events. We believe that SRK181 has an immense potential to increase response rates to checkpoint inhibitors and change medical care for cancer patients across multiple solid tumor types. In addition to these two clinical aspects, there are many potential opportunities for us to extend our science, whether it's additional indications additional tumor types or treatment settings, or additional growth factors to start with. And furthermore, we have an important partnership with Gilead around fibrosis, which continues to progress well. This collaboration is another proof point of the attractiveness of our platform and our approach. So with that, I will turn it over to Young Chung, our Chief Medical Officer. Young? Thanks, Tony.